Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
| ▸ | MC3R | P41968 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.30 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.30 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551511 | 1.00 | CDK1 (0.34) | CDK1CCNB1CCNE1CDK2HRH4 | |
| SCHEMBL2775208 | 0.81 | GDA (0.32) | ADORA2AADORA1PIK3CDPOLBADORA3 | |
| SCHEMBL12311046 | 0.78 | ADORA2A (0.46) | CDK1CCNB1CCNE1CDK2HRH4 | |
| SCHEMBL7617554 | 0.78 | CDK1 (0.37) | CDK1CCNB1CCNE1CDK2HRH4 | |
| Xylose SCHEMBL25306145 | 0.78 | AHCY (0.30) | — | |
| SCHEMBL12261690 | 0.74 | CDK1 (0.35) | CDK1ADORA2AADORA1PIK3CDPOLB | |
| SCHEMBL17226007 | 0.70 | CDK1 (0.55) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL9466617 | 0.67 | ADORA2A (0.38) | ADORA2AADORA1PIK3CDPOLBADORA3 | |
| SCHEMBL12283253 | 0.67 | CDK1 (0.35) | CDK1CCNB1CCNE1CDK2ADORA2A | |
| SCHEMBL11556607 | 0.67 | CDK1 (0.54) | CDK1ADORA2AADORA1PIK3CDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3516077-A1 | METHODS AND COMPOSITIONS FOR DETECTING ANALYTES | Alveo Technologies Inc. (US) | 2019-07-31 | — | — | EP | claimed |
| WO-2018057647-A1 | METHODS AND COMPOSITIONS FOR DETECTING ANALYTES | ALVEO TECHNOLOGIES, INC. (US) | 2018-03-29 | — | — | WO | claimed |
| US-12565661-B2 | Compositions and methods for weed control | SYNGENTA CROP PROTECTION AG (CH) | 2026-03-03 | — | — | US | disclosed |
| US-20250375450-A1 | SMARCA2/4 INHIBITION AS A STRATEGY TO TREAT TUMORS THAT HARBOR ABERRANT BAF ASSEMBLIES | UNIV TEXAS (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250346938-A1 | ATP-DEPENDENT C-TERMINAL MODIFICATION OF POLYPEPTIDES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-13 | — | — | US | disclosed |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-07 | — | — | US | disclosed |
| US-12331343-B2 | FAMIN assay methods | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-17 | — | — | US | disclosed |
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | UNIV CALIFORNIA (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4460294-A2 | SMARCA2/4 INHIBITION AS A STRATEGY TO TREAT TUMORS THAT HARBOR ABERRANT BAF ASSEMBLIES | Board of Regents, The University of Texas System (US) | 2024-11-13 | — | — | EP | disclosed |
| EP-4452416-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-118786129-A | Covalent binding inhibitors of G12S, G D and/or G12E mutants of K-RAS GTPases | 加利福尼亚大学董事会 | 2024-10-15 | — | — | CN | disclosed |
| WO-2002010358-A2 | NUCLEOTIDE INCORPORATING ENZYMES | MAXYGEN, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| US-6221640-B1 | Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same | CUBIST PHARMACEUTICALS, INC. | 2001-04-24 | — | — | US | disclosed |
| WO-2001016357-A2 | NOVEL TARGET FOR ANTIPARASITIC AGENTS AND INHIBITORS THEREOF | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2001-03-08 | — | — | WO | disclosed |
| US-6174713-B1 | NUCLEIC ACID WHICH CODES FOR PORTION OF ENZYME WHICH HAS CATALYTIC OR BINDING FUNCTION; FOR SCREENING FUNGICIDES, ANTIBIOTICS, AND ENZYME INHIBITORS | CUBIST PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | disclosed |
| WO-2000036082-A2 | NOVEL FUNGAL mRNA CAPPING ENZYMES, AND METHODS OF USING THE SAME | QUESTCOR PHARMACEUTICALS, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0715721-B1 | PHOSPHATE ASSAY | MEDICAL RES COUNCIL (GB) | 1999-11-10 | — | — | EP | disclosed |
| US-5898069-A | PHOSPHATE-BINDING PROTEIN CONTAINING (I) AN INORGANIC PHOSPHATE ION BINDING SITE AND (II) A DETECTABLE LABEL THAT PRODUCES A SIGNAL WHOSE AMPLITUDE CHANGES DETECTABLY UPON THE BINDING OF INORGANIC PHOSPHATE ION TO THE BINDING SITE | MEDICAL RESEARCH COUNCIL (GB) | 1999-04-27 | — | — | US | disclosed |
| EP-0715721-A1 | PHOSPHATE ASSAY | MEDICAL RESEARCH COUNCIL (GB) | 1996-06-12 | — | — | EP | disclosed |
| WO-1995002825-A1 | PHOSPHATE ASSAY | MEDICAL RESEARCH COUNCIL (GB) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565661-B2 | Compositions and methods for weed control | RNGTT, DDT, TYMP | CDK1 1800/4885CCNB1 1060/4885CCNE1 593/4885 |
| US-20250059187-A1 | COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE | KRAS, HRAS, NRAS | CDK1 587/4885CCNB1 811/4885CCNE1 312/4885 |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | ADSL, SLC35B2, ADORA1 | CDK1 2222/4885CCNB1 3004/4885CCNE1 3710/4885 |
| US-20250375450-A1 | SMARCA2/4 INHIBITION AS A STRATEGY TO TREAT TUMORS THAT HARBOR ABERRANT BAF ASSEMBLIES | SMARCA4, SMARCE1, SMARCC1 | CDK1 974/4885CCNB1 1248/4885CCNE1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.